Since EGFR mutant NSCLC patients respond to EGFR TKIs clinically, adaptive responses do not seem to impact the initial response to EGFR inhibition, although they may play a role in secondary resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.